2016
DOI: 10.1002/jnr.23855
|View full text |Cite
|
Sign up to set email alerts
|

Sex differences in stroke therapies

Abstract: Stroke is the 5th leading cause of death and acquired disability in aged populations. Women are disproportionally affected by stroke, having a higher incidence and worse outcomes than men. Numerous preclinical studies have discovered novel therapies for the treatment of stroke, but almost all of these were found to be unsuccessful in clinical trials. Despite known sex differences in occurrence and severity of stroke, few therapeutics, both preclinically and clinically, take into account possible sex difference… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
43
0

Year Published

2016
2016
2023
2023

Publication Types

Select...
4
2

Relationship

0
6

Authors

Journals

citations
Cited by 65 publications
(46 citation statements)
references
References 132 publications
(169 reference statements)
1
43
0
Order By: Relevance
“…It has been determined that early responses with tPA are more effective in women . Research shows that males are more likely to receive tPA as a therapeutic option, whereas women may be excluded owing to outside risk factors (ie, hypertension) . Furthermore, certain experimental anti‐inflammatory treatments, such as minocycline, which inhibits the PARP‐1 pathway, are more effective in males in both preclinical and clinical studies .…”
Section: Resultsmentioning
confidence: 99%
See 2 more Smart Citations
“…It has been determined that early responses with tPA are more effective in women . Research shows that males are more likely to receive tPA as a therapeutic option, whereas women may be excluded owing to outside risk factors (ie, hypertension) . Furthermore, certain experimental anti‐inflammatory treatments, such as minocycline, which inhibits the PARP‐1 pathway, are more effective in males in both preclinical and clinical studies .…”
Section: Resultsmentioning
confidence: 99%
“…108 Research shows that males are more likely to receive tPA as a therapeutic option, whereas women may be excluded owing to outside risk factors (ie, hypertension). 109 Furthermore, certain experimental anti-inflammatory treatments, such as minocycline, which inhibits the PARP-1 pathway, are more effective in males in both preclinical and clinical studies. 109,110 Lastly, IGF-1, which can be microglial-regulated, has shown promise as treatment in estrogen-deficient middle-aged females by reducing stroke-induced damage and motor impairment in the aging brain.…”
Section: Con Clus Ionmentioning
confidence: 99%
See 1 more Smart Citation
“…In contrast, stroke patients were often middle-aged (40-60 years old, 54.8%) or elderly (>60 years old, 45.2%), consisting of both males and females, and were always enrolled in clinical trials without selection (see Fig 7E, F). 32 Moreover, there is experimental evidence that cell donors' and recipients' ages can influence cell treatment efficacy, particularly in commonly applied MNC populations. However, this kind of influence cannot be excluded simply due to the very limited number of studies assessing female and aged individuals.…”
Section: Recipient Sex and Agementioning
confidence: 99%
“…In previous investigations, Louise McCullough has reported neuronal utilization of distinct cell death pathways in a mouse model of ischemic cell death (McCullough, 2005). In this issue, Sex differences in stroke therapies (Sohrabji et al, 2017) explores the basis for altering stroke treatment algorithms.…”
mentioning
confidence: 99%